Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emanuel Raschi

Showing results (41-50 of 213) with videos related to

Pageof 22
Sort By:
European Journal of Cancer (Oxford, England : 1990)|December 5, 2025
Letter Re: Tarlatamab-induced immune-related adverse events: Real-world pharmacovigilance study using the FAERS databaseEmanuel Raschi, Charles Khouri, Elisabetta Poluzzi, et al.
Expert Opinion on Pharmacotherapy|March 29, 2019
Dapagliflozin and cardiovascular outcomes: anything else to DECLARE?Emanuel Raschi, Elisabetta Poluzzi, Giulio Marchesini, et al.
Drug Safety|April 9, 2017
Drug-Induced Arrhythmia: Bridging the Gap Between Pathophysiological Knowledge and Clinical PracticeElisabetta Poluzzi, Emanuel Raschi, Igor Diemberger, et al.
Pharmacological Research|March 11, 2008
The hERG K+ channel: target and antitarget strategies in drug developmentEmanuel Raschi, Valentina Vasina, Elisabetta Poluzzi, et al.
European Journal of Internal Medicine|January 28, 2020
Assessing the association between fluoroquinolones and emerging adverse drug reactions raised by regulatory agencies: An umbrella reviewMilo Gatti, Matteo Bianchin, Emanuel Raschi, et al.
Pharmacoepidemiology and Drug Safety|April 10, 2009
Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS)Elisabetta Poluzzi, Emanuel Raschi, Ugo Moretti, et al.
Internal and Emergency Medicine|April 27, 2018
ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations-authors' replyEmanuel Raschi, Igor Diemberger, Benilde Cosmi, et al.
Internal and Emergency Medicine|September 25, 2017
ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectationsEmanuel Raschi, Igor Diemberger, Benilde Cosmi, et al.
Clinical Pharmacology and Therapeutics|June 5, 2026
Major Adverse Cardiac Events with Ondansetron: The Role of Observational Evidence to Inform Actionable Safer Prescribing in Cardio-OncologyEmanuel Raschi, Igor Diemberger, Elisabetta Poluzzi, et al.
Drug Safety|August 5, 2020
Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological BasisMilo Gatti, Elisabetta Poluzzi, Fabrizio De Ponti, et al.
Pageof 22

Showing results (41-50 of 213) with videos related to

Sort By:
Pageof 22
European Journal of Cancer (Oxford, England : 1990)|December 5, 2025
Letter Re: Tarlatamab-induced immune-related adverse events: Real-world pharmacovigilance study using the FAERS databaseEmanuel Raschi, Charles Khouri, Elisabetta Poluzzi, et al.
Expert Opinion on Pharmacotherapy|March 29, 2019
Dapagliflozin and cardiovascular outcomes: anything else to DECLARE?Emanuel Raschi, Elisabetta Poluzzi, Giulio Marchesini, et al.
Drug Safety|April 9, 2017
Drug-Induced Arrhythmia: Bridging the Gap Between Pathophysiological Knowledge and Clinical PracticeElisabetta Poluzzi, Emanuel Raschi, Igor Diemberger, et al.
Pharmacological Research|March 11, 2008
The hERG K+ channel: target and antitarget strategies in drug developmentEmanuel Raschi, Valentina Vasina, Elisabetta Poluzzi, et al.
European Journal of Internal Medicine|January 28, 2020
Assessing the association between fluoroquinolones and emerging adverse drug reactions raised by regulatory agencies: An umbrella reviewMilo Gatti, Matteo Bianchin, Emanuel Raschi, et al.
Pharmacoepidemiology and Drug Safety|April 10, 2009
Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS)Elisabetta Poluzzi, Emanuel Raschi, Ugo Moretti, et al.
Internal and Emergency Medicine|April 27, 2018
ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations-authors' replyEmanuel Raschi, Igor Diemberger, Benilde Cosmi, et al.
Internal and Emergency Medicine|September 25, 2017
ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectationsEmanuel Raschi, Igor Diemberger, Benilde Cosmi, et al.
Clinical Pharmacology and Therapeutics|June 5, 2026
Major Adverse Cardiac Events with Ondansetron: The Role of Observational Evidence to Inform Actionable Safer Prescribing in Cardio-OncologyEmanuel Raschi, Igor Diemberger, Elisabetta Poluzzi, et al.
Drug Safety|August 5, 2020
Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological BasisMilo Gatti, Elisabetta Poluzzi, Fabrizio De Ponti, et al.
Pageof 22